Sustained increase of HDL cholesterol over a 72-week period in HIV-infected patients exposed to an antiretroviral regimen including lopinavir/ritonavir.
Metabolic disorders are a major concern during antiretroviral therapy, especially for their potential to increase cardiovascular disease risk. In a multicenter, prospective study conducted in patients exposed to an antiretroviral regimen including lopinavir boosted with ritonavir, an early and sustained increase of high-density lipoprotein cholesterol was observed over a 72-week period. This increase was positively correlated with the exposure to lopinavir/ritonavir during the first 24 weeks.
Meynard
Jean-Luc
JL
Service des maladies infectieuses et tropicales, Assistance Publique-Hôpitaux de Paris, Paris, France.
Lacombe
Karine
K
Poirier
Jean-Marie
JM
Massot
Olivier
O
Lefebvre
Bénédicte
B
Bouchaud
Olivier
O
Guiard-Schmidt
Jean-Baptiste
JB
Martinez
Alvaro
A
Benlian
Pascale
P
Girard
Pierre-Marie
PM
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage; D008076:Cholesterol, HDL / Q000378:metabolism*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics; D015497:HIV-1; D006801:Humans; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D011744:Pyrimidinones / Q000008:administration & dosage / Q000493:pharmacokinetics; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D019438:Ritonavir / Q000008:administration & dosage / Q000493:pharmacokinetics; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D008076:Cholesterol, HDL; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D061466:Lopinavir; D019438:Ritonavir